Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients.

Literature DB >> 7533432

A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients.

R Shapiro¹, M L Jordan, V P Scantlebury, C Vivas, J J Fung, J McCauley, P Randhawa, A J Demetris, W Irish, A Jain.

Abstract

Entities: Chemical Species

Mesh：

Substances：

Year: 1995 PMID： 7533432 PMCID： PMC2950626

Source DB: PubMed Journal: Transplant Proc ISSN： 0041-1345 Impact factor: 1.066

× No keyword cloud information.

23 in total

Review 1. Historical development of brequinar sodium as a new immunosuppressive drug for transplantation.

Authors: L Makowka; F Chapman; D V Cramer
Journal: Transplant Proc Date: 1993-06 Impact factor: 1.066

2. FK 506 for liver, kidney, and pancreas transplantation.

Authors: T E Starzl; S Todo; J Fung; A J Demetris; R Venkataramman; A Jain
Journal: Lancet Date: 1989-10-28 Impact factor: 79.321

3. Liver, kidney, and thoracic organ transplantation under FK 506.

Authors: S Todo; J J Fung; T E Starzl; A Tzakis; A J Demetris; R Kormos; A Jain; M Alessiani; S Takaya; R Shapiro
Journal: Ann Surg Date: 1990-09 Impact factor: 12.969

4. Kidney transplantation under FK 506.

Authors: T E Starzl; J Fung; M Jordan; R Shapiro; A Tzakis; J McCauley; J Johnston; Y Iwaki; A Jain; M Alessiani
Journal: JAMA Date: 1990-07-04 Impact factor: 56.272

5. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs.

Authors: N Murase; T E Starzl; A J Demetris; L Valdivia; M Tanabe; D Cramer; L Makowka
Journal: Transplantation Date: 1993-04 Impact factor: 4.939

6. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation.

Authors: B P Griffith; K Bando; R L Hardesty; J M Armitage; R J Keenan; S M Pham; I L Paradis; S A Yousem; K Komatsu; H Konishi
Journal: Transplantation Date: 1994-03-27 Impact factor: 4.939

7. FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression.

Authors: M L Jordan; R Shapiro; C A Vivas; V P Scantlebury; P Rhandhawa; G Carrieri; J McCauley; A J Demetris; A Tzakis; J J Fung
Journal: Transplantation Date: 1994-03-27 Impact factor: 4.939

8. Small intestinal transplantation in humans with or without the colon.

Authors: S Todo; A Tzakis; J Reyes; K Abu-Elmagd; H Furukawa; B Nour; A Casavilla; K Nakamura; J Fung; A J Demetris
Journal: Transplantation Date: 1994-03-27 Impact factor: 4.939

9. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement.

Authors: A G Tzakis; C Ricordi; R Alejandro; Y Zeng; J J Fung; S Todo; A J Demetris; D H Mintz; T E Starzl
Journal: Lancet Date: 1990-08-18 Impact factor: 79.321

10. Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression.

Authors: S Todo; J J Fung; T E Starzl; A Tzakis; H Doyle; K Abu-Elmagd; A Jain; R Selby; O Bronsther; W Marsh
Journal: Ann Surg Date: 1994-09 Impact factor: 12.969

15 in total

1. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients.

Authors: R Shapiro; M L Jordan; V P Scantlebury; C Vivas; J W Marsh; J McCauley; J Johnston; P Randhawa; W Irish; H A Gritsch; R Naraghi; T R Hakala; J J Fung; T E Starzl
Journal: Transplantation Date: 1999-02-15 Impact factor: 4.939

2. Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression.

Authors: R Shapiro; M L Jordan; V P Scantlebury; C Vivas; H A Gritsch; J McCauley; D McQuitty; P Randhawa; W Irish; J McMichael; T R Hakala; R L Simmons; J J Fung; T E Starzl
Journal: Transplant Proc Date: 1998-06 Impact factor: 1.066

3. Tacrolimus in renal transplantation.

Authors: R Shapiro; M L Jordan; V P Scantlebury; C Vivas; H A Gritsch; J McCauley; D Ellis; N Gilboa; S Lombardozzi-Lane; P Randhawa; A J Demetris; W Irish; T R Hakala; R L Simmons; J J Fung; T E Starzl
Journal: Transplant Proc Date: 1996-08 Impact factor: 1.066

A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients.

Review 1. Historical development of brequinar sodium as a new immunosuppressive drug for transplantation.

2. FK 506 for liver, kidney, and pancreas transplantation.

3. Liver, kidney, and thoracic organ transplantation under FK 506.

4. Kidney transplantation under FK 506.

5. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs.

6. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation.

7. FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression.

8. Small intestinal transplantation in humans with or without the colon.

9. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement.

10. Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression.

1. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients.

2. Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression.

3. Tacrolimus in renal transplantation.

4. Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature.

Review 5. The use of tacrolimus in renal transplantation.

6. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

Review 7. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management.

Review 8. [Diabetes and heart transplantation].

9. Renal transplantation at the University of Pittsburgh: the impact of FK506.

10. Cost evaluation of basiliximab treatment for renal transplant patients in Japan.